PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms

Area of Science:

• Oncology
• Genetics
• Pharmacology

Background:

• Poly (ADP-ribose) polymerase (PARP) inhibitors have demonstrated significant clinical efficacy in ovarian cancer treatment.
• Approved PARP inhibitors include olaparib, rucaparib, and niraparib, primarily used in the United States.
• Homologous recombination deficiency (HRD) and platinum sensitivity are key biomarkers for predicting patient response.

Purpose of the Study:

• To review current understanding of biomarkers predicting PARP inhibitor response in ovarian cancer.
• To explore mechanisms of resistance to PARP inhibitors and strategies for overcoming them.
• To discuss the potential of combining PARP inhibitors with other therapies for broader application.

Main Methods:

• Analysis of preclinical data from cell lines and patient-derived xenografts to identify HRD-associated gene aberrations.
• Review of clinical trial data focusing on genomic scar analysis for biomarker discovery.
• Investigation into mechanisms of acquired or intrinsic resistance to PARP inhibitors.

Main Results:

• HRD and platinum sensitivity are established biomarkers for PARP inhibitor efficacy.
• Genomic scar analysis is utilized in clinical trials to refine biomarker identification.
• Research is ongoing to understand and combat resistance mechanisms, including combination therapies.

Conclusions:

• PARP inhibitors are valuable in ovarian cancer, with HRD and platinum sensitivity as crucial predictive biomarkers.
• Overcoming resistance and expanding utility to BRCA-proficient tumors through combination therapies are key future directions.
• Further research is essential to optimize PARP inhibitor strategies and patient selection for ovarian cancer treatment.